Intravenous nitroglycerin in acute myocardial infarction

Area of Science:

• Cardiology
• Pharmacology

Background:

• Intravenous nitroglycerin was previously contraindicated in acute myocardial infarction due to potential hypotension and tachycardia.
• Its use in experimental models and preliminary human studies showed promise for managing acute myocardial ischemia.

Purpose of the Study:

• To evaluate the efficacy and safety of intravenous nitroglycerin in patients with acute myocardial infarction.
• To assess its impact on infarct size, hemodynamics, and cardiac failure.

Main Methods:

• A randomized prospective study involving 85 patients with acute myocardial infarction.
• Intravenous nitroglycerin administration and assessment of infarct size, S-T segment elevation, and hemodynamic parameters.

Main Results:

• Intravenous nitroglycerin was associated with a 36% reduction in infarct size in patients with inferior infarction (p < 0.05).
• No significant effect on infarct size was observed in patients with anterior infarction.
• The treatment was effective and safe for managing cardiac failure in this patient group.

Conclusions:

• Intravenous nitroglycerin is a safe and effective treatment option for cardiac failure in acute myocardial infarction.
• Its role in routine infarct size reduction requires further investigation, particularly differentiating between infarction locations.